Premium
Management of Epstein–Barr Virus‐induced Post‐transplant Lymphoproliferative Disease in Recipients of Solid Organ Transplantation
Author(s) -
Green Michael
Publication year - 2001
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1034/j.1600-6143.2001.10202.x
Subject(s) - medicine , immunosuppression , lymphoproliferative disease , lymphoproliferative disorders , epstein–barr virus , immunology , organ transplantation , immunotherapy , transplantation , disease , solid organ , virus , lymphoma , immune system , pathology
The optimal management of Epstein–Barr virus (EBV)‐induced post‐transplant lymphoproliferative diseases (PTLD) remains controversial. While withdrawal or reduction of immunosuppression is widely accepted as the strategy for the treatment of EBV/PTLD, the role of additional therapeutic interventions remains less clear. Newer strategies, including anti‐B‐cell monoclonal antibodies and adoptive immunotherapy offer the promise of impaired efficacy and outcome against EBV disease, but lack data demonstrating how and when to use these approaches. The current review provides an overview of potential strategies and presents guidelines for the management of EBV/PTLD in solid‐organ transplant recipients.